We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+0.49%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.85B
AUM Growth
-$390M
Cap. Flow
-$60.3M
Cap. Flow %
-0.61%
Top 10 Hldgs %
29.91%
Holding
227
New
13
Increased
57
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
AMED
Amedisys
AMED
+$50.4M
2
FATE icon
Fate Therapeutics
FATE
+$49M
3
RVMD icon
Revolution Medicines
RVMD
+$46.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$43.8M
5
EPIX
ESSA Pharma
EPIX
+$40.9M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$301M
2
HALO icon
Halozyme
HALO
+$54.5M
3
CRL icon
Charles River Laboratories
CRL
+$47.7M
4
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$34.2M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.84%
2 Industrials 0.82%
3 Technology 0.59%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
76
DELISTED
Exact Sciences
EXAS
$41M 0.42%
429,273
+153,600
+56% +$16.2M
EPIX
77
DELISTED
ESSA Pharma
EPIX
$40.3M 0.41%
5,034,814
+2,575,000
+105% +$40.9M
MRSN
78
DELISTED
Mersana Therapeutics
MRSN
$40.2M 0.41%
170,440
+52,800
+45% +$15.4M
KZR
79
DELISTED
Kezar Life Sciences
KZR
$39.2M 0.4%
453,315
– –
PHR icon
80
Phreesia
PHR
$659M
$38.4M 0.39%
622,542
– –
HALO icon
81
Halozyme
HALO
$9.21B
$37.5M 0.38%
921,500
-1,302,966
-59% -$54.5M
HCM icon
82
HUTCHMED
HCM
$1.93B
$36.8M 0.37%
1,006,147
+141,387
+16% +$5.56M
TFX icon
83
Teleflex
TFX
$5.95B
$36.8M 0.37%
97,818
-2,343
-2% -$912K
HCAT icon
84
Health Catalyst
HCAT
$160M
$36.4M 0.37%
727,233
-26,388
-4% -$1.44M
MASI
85
DELISTED
Masimo
MASI
$34.6M 0.35%
127,713
– –
BIO icon
86
Bio-Rad Laboratories Class A
BIO
$8.17B
$34.3M 0.35%
46,015
-41,286
-47% -$30.9M
TXG icon
87
10x Genomics
TXG
$5.43B
$33.9M 0.34%
232,672
– –
COO icon
88
Cooper Companies
COO
$13.9B
$30.7M 0.31%
297,064
– –
ABBV icon
89
AbbVie
ABBV
$448B
$30.5M 0.31%
282,900
-41,300
-13% -$4.72M
QTRX icon
90
Quanterix
QTRX
$182M
$29.6M 0.3%
593,819
-43,996
-7% -$2.27M
BDTX icon
91
Black Diamond Therapeutics
BDTX
$102M
$29.3M 0.3%
3,463,000
– –
ATRC icon
92
AtriCure
ATRC
$1.78B
$29.1M 0.3%
418,016
+43,598
+12% +$3.36M
ILMN icon
93
Illumina
ILMN
$28.1B
$28.4M 0.29%
72,094
-5,345
-7% -$2.46M
TDOC icon
94
Teladoc Health
TDOC
$1.72B
$27.4M 0.28%
215,906
-42,042
-16% -$6.12M
NEO icon
95
NeoGenomics
NEO
$1.87B
$27.1M 0.28%
561,683
-256,630
-31% -$11.9M
CRL icon
96
Charles River Laboratories
CRL
$10.6B
$26.1M 0.27%
63,329
-114,941
-64% -$47.7M
NVRO
97
DELISTED
NEVRO CORP.
NVRO
$25M 0.25%
214,956
+31,755
+17% +$4.16M
AXSM icon
98
Axsome Therapeutics
AXSM
$11.7B
$24.8M 0.25%
752,945
+400,924
+114% +$15.6M
RMD icon
99
ResMed
RMD
$28.6B
$23.2M 0.24%
88,145
– –
OM icon
100
Outset Medical
OM
$75.6M
$22.6M 0.23%
30,471
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2021 Portfolio in Review

As of Q3 2021, Bellevue Group held 227 positions worth $9.85B, down 3.8% from $10.2B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q3 2021 filing shows 13 new, 57 increased, 57 reduced and 7 closed positions. Its largest new stake was Sarepta Therapeutics: 569,168 shares worth $52.6M. The largest sale was Moderna, an estimated $301M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2021 buy was Sarepta Therapeutics: 569,168 shares worth $52.6M.
  • Bellevue Group added most to Amedisys in Q3 2021, an estimated $50.4M increase.
  • Bellevue Group's biggest Q3 2021 reduction was Moderna, cutting an estimated $301M.
  • Bellevue Group fully exited Eargo, Inc. Common Stock in Q3 2021, selling an estimated $17.3M.
  • Bellevue Group's ten largest holdings make up 30% of its $9.85B portfolio in Q3 2021.
  • Bellevue Group opened 13 new positions and closed 7 in Q3 2021.
  • Bellevue Group's portfolio value fell 3.8% quarter-over-quarter to $9.85B.

Based on Bellevue Group's 13F filing for Q3 2021, filed 12 Nov 2021.